Herbal Preparation STW 5 for Functional Gastrointestinal Disorders: Clinical Experience in Everyday Practice
- PMID: 29421814
- DOI: 10.1159/000485411
Herbal Preparation STW 5 for Functional Gastrointestinal Disorders: Clinical Experience in Everyday Practice
Abstract
Background: The most common functional gastrointestinal disorders (FGID) are functional dyspepsia (FD) and irritable bowel syndrome (IBS), with a prevalence in the general population of 15-20% (FD) and 10% (IBS), respectively. The complexity of pathophysiologic mechanisms and limitations in therapeutic options make the management of FD and IBS patients a challenge in routine clinical practice.
Summary: Syndromes classified as FGID frequently overlap, and coexist with gastroesophageal reflux disease (GERD). Patients with overlapping symptoms are more likely to seek medical care. The challenge for routine clinical practice is to find the best approach for treatment of multiple symptoms. STW 5, a combination of 9 herbal extracts, was shown to have multi-target effects: it normalizes the disturbed gastrointestinal motility, alleviates hypersensitivity, inhibits inflammation, suppresses gastric hypersecretion, and modulates the microbiota. Controlled randomized studies proved STW 5 to be efficacious both in FD and IBS, with control over the full spectrum of upper and lower gastrointestinal symptoms. STW 5 reduced concomitant heartburn in FD patients. STW 5 was well tolerated in the examined populations, independent of concomitant diseases and concomitant medication. Key Messages: The clinical use of the herbal preparation STW 5 in FD and IBS is evidence-based. STW 5 is an example for the concept of multi-target therapy. It offers treatment opportunities in routine clinical practice with high prevalence of overlap of FGID and concomitant GERD. Considering that FD and IBS are typically chronic and recurrent conditions, the clinically observed good tolerability and safety of STW 5 is an advantage.
Keywords: Functional dyspepsia; Heartburn; Irritable bowel syndrome; STW 5; Safety.
© 2018 The Author(s) Published by S. Karger AG, Basel.
Similar articles
-
STW 5 (Iberogast) Therapy in Gastrointestinal Functional Disorders.Dig Dis. 2017;35 Suppl 1:25-29. doi: 10.1159/000485410. Epub 2018 Feb 8. Dig Dis. 2017. PMID: 29421817 Review.
-
Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target.Dig Dis. 2017;35 Suppl 1:18-24. doi: 10.1159/000485456. Epub 2018 Feb 8. Dig Dis. 2017. PMID: 29421789 Review.
-
Functional gastrointestinal disorders in children: Effectivity, safety, and tolerability of the herbal preparation STW-5 (Iberogast®) in general practice.Complement Ther Med. 2022 Dec;71:102873. doi: 10.1016/j.ctim.2022.102873. Epub 2022 Aug 23. Complement Ther Med. 2022. PMID: 35998755
-
STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders.Wien Med Wochenschr. 2013 Feb;163(3-4):65-72. doi: 10.1007/s10354-012-0169-x. Epub 2012 Dec 20. Wien Med Wochenschr. 2013. PMID: 23263639 Free PMC article. Review.
-
Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors.Dig Dis Sci. 2019 Feb;64(2):480-486. doi: 10.1007/s10620-018-5343-6. Epub 2018 Oct 27. Dig Dis Sci. 2019. PMID: 30368683
Cited by
-
Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches.Dig Dis. 2020;38(4):269-279. doi: 10.1159/000504570. Epub 2019 Nov 26. Dig Dis. 2020. PMID: 31770769 Free PMC article. Review.
-
MODERN APPROACH TO DYSPEPSIA.Acta Clin Croat. 2021 Dec;60(4):731-738. doi: 10.20471/acc.2021.60.04.21. Acta Clin Croat. 2021. PMID: 35734496 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources